Cargando…

Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer

BACKGROUND: Although the use of contraceptive hormones is a risk factor for development of breast cancer, level of risk is unknown; thus the current research was conducted to investigate the effect of factors related to fertility and hormone use on risk of breast cancer in women aged under 50 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Moradinazar, Mehdi, Marzbani, Behjat, Shahebrahimi, Karoon, Shahabadi, Sara, Marzbani, Behnaz, Moradinazar, Zeinab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938198/
https://www.ncbi.nlm.nih.gov/pubmed/31920374
http://dx.doi.org/10.2147/BCTT.S218394
_version_ 1783484001813528576
author Moradinazar, Mehdi
Marzbani, Behjat
Shahebrahimi, Karoon
Shahabadi, Sara
Marzbani, Behnaz
Moradinazar, Zeinab
author_facet Moradinazar, Mehdi
Marzbani, Behjat
Shahebrahimi, Karoon
Shahabadi, Sara
Marzbani, Behnaz
Moradinazar, Zeinab
author_sort Moradinazar, Mehdi
collection PubMed
description BACKGROUND: Although the use of contraceptive hormones is a risk factor for development of breast cancer, level of risk is unknown; thus the current research was conducted to investigate the effect of factors related to fertility and hormone use on risk of breast cancer in women aged under 50 years old in the west of Iran. METHODS: In this case-control study, all incidence cases of breast cancer aged between 25–49 years old (n=212) were selected. Twice as many as the case group, the individuals referred to other outpatient sections of the same hospital at the time of study and up to 2 years after the follow-up not diagnosed with breast or other cancers were selected as a control group. The data were collected using healthy fertility program and middle-aged periodical care forms developed by Iran’s Ministry of Health (MOH). RESULTS: After controlling for confounding variables, history of hormonal use for contraception (OR=2.02, 95% CI=1.2–3.3) and hormone therapies (OR=1.9, 95% CI=1.2–3.04) were identified as factors increasing the risk of breast cancer. Dose-response relationships between breast cancer and the use of hormones for contraception and hormone therapy indicated that these factors increased the risk of breast cancer. The risk was found to be higher in women who had been under hormone therapy for more than 120 months. With an increase in the age of the first menstruation, risk of breast cancer increased linearly, but with an increase in the age of the first pregnancy, risk of breast cancer increased exponentially. After 20 years of age, the risk increased with a steeper slope. CONCLUSION: Considering the effect of hormone therapy and fertility factors on breast cancer and changeability of listed risk factors, the researchers suggest planning for sensitizing, increasing the awareness, and educating women and professionals regarding the influence of fertility and hormonal factors including pregnancy at lower ages, minimizing the use of hormones for contraception, and hormone therapy.
format Online
Article
Text
id pubmed-6938198
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69381982020-01-09 Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer Moradinazar, Mehdi Marzbani, Behjat Shahebrahimi, Karoon Shahabadi, Sara Marzbani, Behnaz Moradinazar, Zeinab Breast Cancer (Dove Med Press) Original Research BACKGROUND: Although the use of contraceptive hormones is a risk factor for development of breast cancer, level of risk is unknown; thus the current research was conducted to investigate the effect of factors related to fertility and hormone use on risk of breast cancer in women aged under 50 years old in the west of Iran. METHODS: In this case-control study, all incidence cases of breast cancer aged between 25–49 years old (n=212) were selected. Twice as many as the case group, the individuals referred to other outpatient sections of the same hospital at the time of study and up to 2 years after the follow-up not diagnosed with breast or other cancers were selected as a control group. The data were collected using healthy fertility program and middle-aged periodical care forms developed by Iran’s Ministry of Health (MOH). RESULTS: After controlling for confounding variables, history of hormonal use for contraception (OR=2.02, 95% CI=1.2–3.3) and hormone therapies (OR=1.9, 95% CI=1.2–3.04) were identified as factors increasing the risk of breast cancer. Dose-response relationships between breast cancer and the use of hormones for contraception and hormone therapy indicated that these factors increased the risk of breast cancer. The risk was found to be higher in women who had been under hormone therapy for more than 120 months. With an increase in the age of the first menstruation, risk of breast cancer increased linearly, but with an increase in the age of the first pregnancy, risk of breast cancer increased exponentially. After 20 years of age, the risk increased with a steeper slope. CONCLUSION: Considering the effect of hormone therapy and fertility factors on breast cancer and changeability of listed risk factors, the researchers suggest planning for sensitizing, increasing the awareness, and educating women and professionals regarding the influence of fertility and hormonal factors including pregnancy at lower ages, minimizing the use of hormones for contraception, and hormone therapy. Dove 2019-12-27 /pmc/articles/PMC6938198/ /pubmed/31920374 http://dx.doi.org/10.2147/BCTT.S218394 Text en © 2019 Moradinazar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Moradinazar, Mehdi
Marzbani, Behjat
Shahebrahimi, Karoon
Shahabadi, Sara
Marzbani, Behnaz
Moradinazar, Zeinab
Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title_full Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title_fullStr Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title_full_unstemmed Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title_short Hormone Therapy and Factors Affecting Fertility of Women Under 50-Year-Old with Breast Cancer
title_sort hormone therapy and factors affecting fertility of women under 50-year-old with breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938198/
https://www.ncbi.nlm.nih.gov/pubmed/31920374
http://dx.doi.org/10.2147/BCTT.S218394
work_keys_str_mv AT moradinazarmehdi hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer
AT marzbanibehjat hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer
AT shahebrahimikaroon hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer
AT shahabadisara hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer
AT marzbanibehnaz hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer
AT moradinazarzeinab hormonetherapyandfactorsaffectingfertilityofwomenunder50yearoldwithbreastcancer